Although TGF-β released locally from BRAF-inhibitor treated melanoma cells appeared to constitute an important mechanism of fibroblast activation, there is also evidence that the introduction of mutant BRAF into melanoma cells increases their secretion of interleukin (IL)-1α that causes tumor-associated fibroblasts to induce immune suppression [228]. This evidence concerns the gene TGFB1 and melanoma.